Skip to main content

Drug Interactions between betrixaban and horse chestnut

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

horse chestnut betrixaban

Applies to: horse chestnut and betrixaban

GENERALLY AVOID: When administered systemically, horse chestnut may theoretically potentiate the effects of anticoagulants, platelet inhibitors and other agents that affect hemostasis, possibly increasing the risk of bleeding and bruising. Horse chestnut contains the coumarin glycosides aesculetin, fraxin, and scopolin.

MANAGEMENT: Patients should consult a healthcare provider before taking any herbal or alternative medicine. Until more information is available, consumption of horse chestnut should preferably be avoided during use of anticoagulants, platelet inhibitors, or other agents that can cause bleeding. In patients who have used horse chestnut extensively prior to receiving these agents, the potential for an interaction should be considered. Close clinical and laboratory monitoring for bleeding complications is recommended. Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, nosebleeds, prolonged bleeding from cuts, bleeding of gums from brushing, red or brown urine, and red or black stools.

References

  1. (2001) "Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals
  2. Heck AM, DeWitt BA, Lukes AL (2000) "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm, 57, 1221-7; quiz 1228-30
  3. Therapeutic Research Faculty (2008) Natural Medicines Comprehensive Database. http://www.naturaldatabase.com

Switch to consumer interaction data

Drug and food interactions

Moderate

betrixaban food

Applies to: betrixaban

ADJUST DOSING INTERVAL: Food reduces the oral bioavailability of betrixaban. When administered with a low-fat (900 calories; 20% fat) or high-fat (900 calories; 60% fat) meal, betrixaban peak plasma concentration (Cmax) and systemic exposure (AUC) decreased relative to administration in the fasting state by an average of 70% and 61%, respectively, with the low-fat meal and 50% and 48%, respectively, with the high-fat meal. The effect of food on betrixaban pharmacokinetics could be observed for up to 6 hours after meal intake.

MANAGEMENT: The manufacturer recommends taking betrixaban at the same time each day with food.

References

  1. (2017) "Product Information. Bevyxxa (betrixaban)." Portola Pharmaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer